Garrett Potter

US Patent:

8318747, Nov 27, 2012

Filed:

Apr 21, 2010

Appl. No.:

12/764249

Inventors:

Tai Wei Ly - San Diego CA, US
Garrett Thomas Potter - San Diego CA, US

Assignee:

Axikin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/4965
A61K 31/439
C07D 241/04

US Classification:

51425502, 544383

Abstract:

Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists of Formula I or II, and pharmaceutical compositions thereof:.

US Patent:

8314116, Nov 20, 2012

Filed:

Sep 24, 2008

Appl. No.:

12/679893

Inventors:

Tai Wei Ly - San Diego CA, US
Garrett Thomas Potter - Redlands CA, US
Marie Chantal Siu-Ying Tran - Arcadia CA, US

Assignee:

Actimis Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 239/47
A61K 31/505

US Classification:

514274, 544317

Abstract:

Provided herein are 2-S-benzyl pyrimidine compounds having CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity, useful for the prophylaxis and treatment of diseases associated with CRTH2 activity, including the treatment of allergic diseases, eosinophil-related diseases and basophil-related diseases.

US Patent:

8563544, Oct 22, 2013

Filed:

Oct 26, 2012

Appl. No.:

13/662080

Inventors:

Garrett Thomas Potter - San Diego CA, US

Assignee:

Axikin Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 211/96
C07D 295/26
C07D 241/08
A61K 31/54
A61K 31/4453
A61K 31/445

US Classification:

5142275, 544 581, 544 582, 544 59

Abstract:

Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists, e. g. , compounds of Formula I, and pharmaceutical compositions thereof: Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.

US Patent:

20110218207, Sep 8, 2011

Filed:

Mar 1, 2011

Appl. No.:

13/038251

Inventors:

Tai Wei Ly - San Diego CA, US
Garrett Thomas Potter - San Diego CA, US

Assignee:

Axikin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/495
C07D 295/26
C07C 311/18
A61P 29/00
A61P 11/06
A61P 1/00
A61P 17/10
A61P 1/04
A61P 35/02
A61P 11/00
A61P 17/06
A61P 19/02
A61P 9/00

US Classification:

51425503, 544383, 558413

Abstract:

Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.

US Patent:

20110230487, Sep 22, 2011

Filed:

Mar 17, 2011

Appl. No.:

13/050831

Inventors:

Tai Wei LY - San Diego CA, US
Garrett Thomas Potter - Redlands CA, US
Jared Andrew Forrester - Castle Rock CO, US

International Classification:

A61K 31/5377
C07D 211/96
A61K 31/4468
C07D 401/12
A61K 31/454
C07D 413/12
C07D 401/04
A61K 31/4545
A61K 31/496
A61P 11/00
A61P 37/08
A61P 1/00
A61P 17/00
A61P 25/28
A61P 9/00
A61P 19/02
C12N 5/07

US Classification:

5142372, 546223, 514329, 546224, 546210, 514326, 546209, 544130, 546190, 514316, 544360, 51425311, 435375

Abstract:

Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.

US Patent:

20130274227, Oct 17, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/830712

Inventors:

Erik Dean RAAUM - San Diego CA, US
Garrett Thomas Potter - San Diego CA, US
Tai Wei Ly - San Diego CA, US

Assignee:

Axikin Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 231/38
A61K 31/4439
C07D 401/12
C07D 405/12
A61K 31/4155
C07D 417/12
A61K 31/427
C07D 403/12
A61K 45/06
A61K 31/506
C07D 409/14
A61K 31/4184
A61K 31/4178
A61K 31/496
A61K 31/5377
A61K 31/454
C07D 409/12
C07F 5/02
A61K 31/69
A61K 31/415

US Classification:

514 64, 514404, 5483717, 514341, 5462754, 5483644, 548205, 514365, 5483641, 5483657, 544316, 514274, 5483651, 5483061, 514394, 5483124, 514397, 544371, 51425405, 544124, 5142365, 546211, 514326, 548110

Abstract:

Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.

US Patent:

20130303492, Nov 14, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/830486

Inventors:

Garrett Thomas Potter - San Diego CA, US
Tai Wei Ly - San Diego CA, US

International Classification:

C07D 231/38
A61K 31/496
A61K 31/506
A61K 31/4439
A61K 31/415
C07D 401/14
C07D 401/12
C07D 409/12
C07D 405/12
A61K 45/06
C07D 413/12
A61K 31/4155
A61K 31/5377
C07D 403/12

US Classification:

514158, 5142308, 5142365, 51425405, 514274, 514316, 514341, 514404, 544140, 544316, 544371, 546187, 5462754, 5483611, 5483644, 5483647, 5483654, 5483657, 5483717

Abstract:

Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.

US Patent:

20140066446, Mar 6, 2014

Filed:

Aug 30, 2013

Appl. No.:

14/015602

Inventors:

Garrett Thomas Potter - Redlands CA, US

Assignee:

Axikin Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 211/96
C07D 265/30
A61K 31/4453
A61K 45/06
A61K 31/5375
C07D 241/04
A61K 31/445
C07D 241/08
A61K 31/495

US Classification:

5142395, 546230, 544383, 544159, 514331, 51425502, 51425212, 51425501, 435375

Abstract:

Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists, e.g., compounds of Formula I, and pharmaceutical compositions thereof: Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.